Nuvation Bio Executive's $90K Stock Purchase Signals Potential Upside

Rhea-AI Filing Summary

Insider Purchase Alert: Colleen Sjogren, Chief Commercial Officer of Nuvation Bio (NUVB), has acquired 50,000 shares of Class A Common Stock on June 16, 2025, at a weighted average price of $1.807 per share, representing a total investment of approximately $90,350.

Following this transaction, Sjogren now beneficially owns 81,000 shares directly, which includes 3,000 shares previously acquired through the company's 2021 Employee Stock Purchase Plan on May 19, 2025. The purchase was executed in multiple transactions with prices ranging from $1.795 to $1.82 per share.

This insider purchase by a senior executive could signal confidence in the company's future prospects. The transaction was reported via Form 4 filing and executed in compliance with securities regulations, with the filing submitted through an attorney-in-fact on June 18, 2025.

Positive

• Chief Commercial Officer made significant open market purchase of 50,000 shares at $1.807 per share, totaling approximately $90,350, demonstrating insider confidence in company

Negative

• None.

Insider Trade Summary

Net Buyer: 50,000 shares ($90,350)

Net Buy 1 txn

Insider Sjogren Colleen

Role Chief Commercial Officer

Bought 50,000 shs ($90K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock	50,000	$1.807	$90K

Holdings After Transaction: Class A Common Stock — 81,000 shares (Direct)

Footnotes (1)

1. The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.795 to $1.82, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Includes 3,000 shares acquired on May 19, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sjogren Colleen

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/16/2025		P		50,000	A	$1.807(1)	81,000(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.795 to $1.82, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

2. Includes 3,000 shares acquired on May 19, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.

	/s/ Stephen Dang, Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of NUVB did Chief Commercial Officer Colleen Sjogren purchase on June 16, 2025?

Colleen Sjogren purchased 50,000 shares of NUVB Class A Common Stock on June 16, 2025 at a weighted-average price of $1.807 per share.

What is the total number of NUVB shares owned by Colleen Sjogren after her June 2025 purchase?

Following the reported transaction, Colleen Sjogren beneficially owned 81,000 shares of NUVB directly. This total includes 3,000 shares previously acquired through the company's 2021 Employee Stock Purchase Plan in May 2025.

What was the price range for NUVB shares purchased by Sjogren in the June 2025 transaction?

The shares were purchased in multiple transactions at prices ranging from $1.795 to $1.82 per share, with a weighted-average price of $1.807.

When did NUVB's Chief Commercial Officer last purchase shares through the Employee Stock Purchase Plan?

According to the filing, Colleen Sjogren acquired 3,000 shares through NUVB's 2021 Employee Stock Purchase Plan on May 19, 2025.